Delcath Systems, Inc. (NASDAQ:DCTH) Shares Acquired by Kennedy Capital Management LLC

Kennedy Capital Management LLC lifted its position in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 89.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 258,782 shares of the company's stock after buying an additional 122,318 shares during the period. Kennedy Capital Management LLC owned approximately 0.81% of Delcath Systems worth $3,116,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Principal Financial Group Inc. acquired a new stake in Delcath Systems during the third quarter worth about $808,000. Baader Bank Aktiengesellschaft acquired a new stake in Delcath Systems during the 4th quarter worth approximately $204,000. Barclays PLC purchased a new position in Delcath Systems in the third quarter valued at approximately $104,000. Private Advisor Group LLC acquired a new position in Delcath Systems during the fourth quarter valued at approximately $153,000. Finally, Jane Street Group LLC purchased a new stake in Delcath Systems during the third quarter worth approximately $110,000. 61.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on DCTH shares. Craig Hallum raised their target price on shares of Delcath Systems from $18.00 to $21.00 and gave the company a "buy" rating in a research note on Friday, January 17th. HC Wainwright increased their target price on Delcath Systems from $22.00 to $24.00 and gave the company a "buy" rating in a research note on Friday, March 7th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, Delcath Systems has a consensus rating of "Moderate Buy" and an average target price of $22.75.

Delcath Systems Price Performance

DCTH traded up $0.08 during trading on Friday, hitting $11.63. The company had a trading volume of 315,097 shares, compared to its average volume of 354,853. The company has a market cap of $388.83 million, a PE ratio of -8.61 and a beta of 0.85. Delcath Systems, Inc. has a 1-year low of $4.62 and a 1-year high of $16.97. The business has a 50-day moving average of $13.12 and a 200-day moving average of $12.26.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last posted its quarterly earnings results on Thursday, March 6th. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. The firm had revenue of $15.10 million during the quarter, compared to analyst estimates of $14.96 million. During the same quarter last year, the business posted ($0.48) earnings per share. Research analysts forecast that Delcath Systems, Inc. will post -0.79 earnings per share for the current year.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.